Cambrian partners with exceptional scientists to bring new classes of medicines to patients in need, built around understanding the deep science of the biological drivers of aging, with the potential to both treat and prevent today’s deadliest diseases. The company’s approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. Their science targets the three key drivers of aging: molecular alterations, cellular dysfunction, and tissue degeneration. Cambrian isn’t a typical drug development company. They combine the knowledge sharing of a company-building VC with the long-term vision of a pharmaceutical company and the entrepreneurial spirit of a biotech startup. They currently have ten companies in their portfolio each with several shots on goal. The first drug to enter the clinic is an AMPK activator a daily oral medication for peripheral artery disease, that also provides the benefit of a day’s worth of exercise.